Psychedelic Drugs in Biomedicine

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial

Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · see citing works

Psychedelics

Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762 · see citing works

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698 · see citing works

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · see citing works

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · see citing works

Modern network science of neurological disorders

Stam, C. J. (2014) · Nature reviews. Neuroscience · doi:10.1038/nrn3801 · Cited by 1,284 · see citing works

The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs.

Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252 · see citing works

Hallucinogens

Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211 · see citing works

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · see citing works

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · see citing works

Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · see citing works

Functional Selectivity and Classical Concepts of Quantitative Pharmacology

Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B. K., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104463 · Cited by 1,119 · see citing works

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932 · see citing works

Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior

González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925 · see citing works

Pilot study of the 5-HT _2A R agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · see citing works

Trace amines: Identification of a family of mammalian G protein-coupled receptors

Borowsky, B., Adham, N., JONES, K. A., Raddatz, R., Artymyshyn, R. P., Ogozalek, K. L., Durkin, M. M., Lakhlani, P. P., Bonini, J. A., Pathirana, S. M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151105198 · Cited by 912 · see citing works

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905 · see citing works

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895 · see citing works

Neural correlates of the LSD experience revealed by multimodal neuroimaging

Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859 · see citing works

Arc/Arg3.1 Is Essential for the Consolidation of Synaptic Plasticity and Memories

Plath, N., Ohana, O., Dammermann, B., Errington, M. L., Schmitz, D., Gross, C., Mao, X., Engelsberg, A., Mahlke, C., Welzl, H., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.08.024 · Cited by 827 · see citing works

Long-term follow-up of psilocybin-facilitated smoking cessation

Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696 · see citing works

Psychometric evaluation of the altered states of consciousness rating scale (OAV)

Studerus, E., Gamma, A., & Vollenweider, F. X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012412 · Cited by 683 · see citing works

Homological scaffolds of brain functional networks

Petri, G., Expert, P., Turkheimer, F., Carhart-Harris, R., Nutt, D., Hellyer, P. J., & Vaccarino, F. (2014) · Journal of The Royal Society Interface · doi:10.1098/rsif.2014.0873 · Cited by 675 · see citing works

Amphetamine, 3,4-Methylenedioxymethamphetamine, Lysergic Acid Diethylamide, and Metabolites of the Catecholamine Neurotransmitters Are Agonists of a Rat Trace Amine Receptor

Bunzow, J. R., Sonders, M. S., Arttamangkul, S., Harrison, L. M., Zhang, G., Quigley, D. I., Darland, T., Suchland, K. L., Pasumamula, S., Kennedy, J. L., et al. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.6.1181 · Cited by 651 · see citing works

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583 · see citing works

Prefrontal Cortex and Social Cognition in Mouse and Man

Bicks, L. K., Koike, H., Akbarian, S., & Morishita, H. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2015.01805 · Cited by 491 · see citing works

Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.

Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476 · see citing works

Crystal Structure of an LSD-Bound Human Serotonin Receptor

Wacker, D., Wang, S., McCorvy, J. D., Betz, R. M., Venkatakrishnan, A., Levit, A., Lansu, K., Schools, Z. L., Che, T., Nichols, D. E., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.033 · Cited by 458 · see citing works

The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network

Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454 · see citing works

Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects

Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.015 · Cited by 409 · see citing works

The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation

Preller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stämpfli, P., Liechti, M. E., Seifritz, E., & Vollenweider, F. X. (2017) · Current Biology · doi:10.1016/j.cub.2016.12.030 · Cited by 402 · see citing works

Enhanced repertoire of brain dynamical states during the psychedelic experience

Tagliazucchi, E., Carhart-Harris, R. L., Leech, R., Nutt, D., & Chialvo, D. R. (2014) · Human Brain Mapping · doi:10.1002/hbm.22562 · Cited by 399 · see citing works

Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators

Berry, M. D. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02501.x · Cited by 389 · see citing works

Psychedelics as Medicines: An Emerging New Paradigm

Nichols, D. E., Johnson, M., & Nichols, C. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.557 · Cited by 373 · see citing works

Epigenetic Priming of Memory Updating during Reconsolidation to Attenuate Remote Fear Memories

Gräff, J., Joseph, N. F., Horn, M. E., Samiei, A., Meng, J., Seo, J., Rei, D., Bero, A. W., Phan, T. X., Wagner, F., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.020 · Cited by 357 · see citing works

Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on Oscillations, N170 Visual-Evoked Potentials, and Visual Hallucinations

Kometer, M., Schmidt, A., Jancke, L., & Vollenweider, F. X. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3007-12.2013 · Cited by 355 · see citing works

Effects of Schedule I drug laws on neuroscience research and treatment innovation

Nutt, D., King, L. A., & Nichols, D. E. (2013) · Nature reviews. Neuroscience · doi:10.1038/nrn3530 · Cited by 338 · see citing works

Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers

Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.010 · Cited by 323 · see citing works

Psilocybin Biases Facial Recognition, Goal-Directed Behavior, and Mood State Toward Positive Relative to Negative Emotions Through Different Serotonergic Subreceptors

Kometer, M., Schmidt, A., Bachmann, R., Studerus, E., Seifritz, E., & Vollenweider, F. X. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.005 · Cited by 298 · see citing works

Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex

González-Maeso, J., Yuen, T., Ebersole, B. J., Wurmbach, E., Lira, A., Zhou, M., Weisstaub, N., Hen, R., Gingrich, J. A., & Sealfon, S. C. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08836.2003 · Cited by 297 · see citing works

Is Pharma Running Out of Brainy Ideas?

Miller, G. (2010) · Science · doi:10.1126/science.329.5991.502 · Cited by 284 · see citing works

Revolution Stalled

Hyman, S. E. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003142 · Cited by 260 · see citing works

Characterization of behavioral and endocrine effects of LSD on zebrafish

Grossman, L., Utterback, E., Stewart, A., Gaikwad, S., Chung, K. M., Suciu, C., Wong, K., Elegante, M. F., Elkhayat, S. I., Tan, J., et al. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.039 · Cited by 247 · see citing works

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA

Mithoefer, M. C., Grob, C. S., & Brewerton, T. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00576-3 · Cited by 239 · see citing works

Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists

Moreno, J. L., Holloway, T. D., Albizu, L., Sealfon, S. C., & González‐Maeso, J. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.01.046 · Cited by 235 · see citing works

Hallucinogen persisting perception disorder: what do we know after 50 years?

Halpern, J. H. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00306-x · Cited by 219 · see citing works

Serotonin 5-Hydroxytryptamine2A Receptor Activation Suppresses Tumor Necrosis Factor-α-Induced Inflammation with Extraordinary Potency

Yu, B., Becnel, J., Zerfaoui, M., Rohatgi, R., Boulares, A. H., & Nichols, C. D. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143461 · Cited by 211 · see citing works

Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities

Soler, J., Elices, M., Franquesa, A., Barker, S., Friedlander, P., Feilding, A., Pascual, J. C., & Riba, J. (2016) · Psychopharmacology · doi:10.1007/s00213-015-4162-0 · Cited by 209 · see citing works

Serotonin 5-HT2A Receptor Activation Blocks TNF-α Mediated Inflammation In Vivo

Nau, F., Yu, B.-N., Martin, D. A., & Nichols, C. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075426 · Cited by 197 · see citing works

Organization of the connections between claustrum and cortex in the mouse

Wang, Q., Ng, L., Harris, J. A., Feng, D. H., Li, Y., Royall, J. J., Oh, S. W., Bernard, A., Sunkin, S. M., Christof Koch, A., et al. (2016) · The Journal of Comparative Neurology · doi:10.1002/cne.24047 · Cited by 197 · see citing works

Trace Amine-Associated Receptor 1 Partial Agonism Reveals Novel Paradigm for Neuropsychiatric Therapeutics

Revel, F. G., Moreau, J., Gainetdinov, R. R., Ferragud, A., Velázquez-Sánchez, C., Sotnikova, T. D., Morairty, S. R., Harmeier, A., Zbinden, K. G., Norcross, R. D., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.014 · Cited by 196 · see citing works

The Transcription Factor Zif268/Egr1, Brain Plasticity, and Memory

Veyrac, A., Besnard, A., Caboche, J., Davis, S., & Laroche, S. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-420170-5.00004-0 · Cited by 184 · see citing works

Automated high-throughput neurophenotyping of zebrafish social behavior

Green, J. B. A., Collins, C. J., Kyzar, E. J., Pham, M., Roth, A., Gaikwad, S., Cachat, J., Stewart, A., Landsman, S., Grieco, F., et al. (2012) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2012.07.017 · Cited by 180 · see citing works

Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety

Dhonnchadha, B. Á. N., Bourin, M., & Hascoët, M. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00311-x · Cited by 165 · see citing works

A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain

Nichols, C. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00405-5 · Cited by 163 · see citing works

Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL/6J mice

Zhang, G., Ásgeirsdóttir, H. N., Cohen, S. J., Munchow, A. H., Barrera, M. P., & Stackman, R. W. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.007 · Cited by 161 · see citing works

Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor α and interleukin-6

Kubera, M., Maes, M. H. J., Kenis, G., Kim, Y., & Lasoń, W. (2005) · Psychiatry Research · doi:10.1016/j.psychres.2004.01.014 · Cited by 146 · see citing works

LSD: My Problem Child

Kohn, B., & Hofmann, A. (1981) · The Antioch Review · doi:10.2307/4638477 · Cited by 146 · see citing works

Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis

Marona‐Lewicka, D., Thisted, R. A., & Nichols, D. E. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2183-9 · Cited by 134 · see citing works

Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects

Müller, F., Lenz, C., Dolder, P. C., Harder, S., Schmid, Y., Lang, U. E., Liechti, M. E., & Borgwardt, S. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.54 · Cited by 128 · see citing works

Effects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology

Kyzar, E. J., Collins, C. J., Gaikwad, S., Green, J. B. A., Roth, A., Monnig, L., El-Ounsi, M., Davis, A., Freeman, A., Capezio, N., et al. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.01.003 · Cited by 120 · see citing works

The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen

Canal, C. E., da Silva, U., Gresch, P. J., Watt, E. E., Sanders‐Bush, E., & Airey, D. C. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1784-0 · Cited by 116 · see citing works

Chemistry and Structure–Activity Relationships of Psychedelics

Nichols, D. E. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_475 · Cited by 114 · see citing works

The hallucinogen d -lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT 1A , D 2 and TAAR 1 receptors

De Gregorio, D., Posa, L., Ochoa-Sanchez, R., McLaughlin, R., Maione, S., Comai, S., & Gobbi, G. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.022 · Cited by 110 · see citing works

Classical hallucinogens and neuroimaging: A systematic review of human studies

dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.026 · Cited by 107 · see citing works

Dopamine and Glutamate Induce Distinct Striatal Splice Forms of Ania-6, an RNA Polymerase II-Associated Cyclin

Berke, J. D., Sgambato, V., Zhu, P.-P., Lavoie, B. A., Vincent, M., Krause, M., & Hyman, S. E. (2001) · Neuron · doi:10.1016/s0896-6273(01)00465-2 · Cited by 97 · see citing works

Revisiting the hippocampal–amygdala pathway in primates: Association with immature-appearing neurons

Fudge, J. L., deCampo, D. M., & Becoats, K. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.03.040 · Cited by 92 · see citing works

Abnormal visual experiences in individuals with histories of hallucinogen use: A web-based questionnaire

Baggott, M. J., Coyle, J., Erowid, E., Erowid, F., & Robertson, L. C. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.09.006 · Cited by 92 · see citing works

Serotonin 5-HT2 receptor activation prevents allergic asthma in a mouse model

Nau, F., Miller, J., Saravia, J., Ahlert, T. A., Yu, B.-N., Happel, K., Cormier, S., & Nichols, C. D. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00138.2013 · Cited by 91 · see citing works

Does phenylethylamine act as an endogenous amphetamine in some patients?

Janssen, P., Leysen, J., Megens, A., & Awouters, F. (1999) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145799001522 · Cited by 88 · see citing works

Psychedelics Recruit Multiple Cellular Types and Produce Complex Transcriptional Responses Within the Brain

Martin, D. A., & Nichols, C. D. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.049 · Cited by 86 · see citing works

Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration

Nichols, C. D., Garcia, E. E., & Sanders-Bush, E. (2003) · Molecular Brain Research · doi:10.1016/s0169-328x(03)00029-9 · Cited by 82 · see citing works

Zif268 / Egr1 gain of function facilitates hippocampal synaptic plasticity and long-term spatial recognition memory

Penke, Z., Morice, É., Veyrac, A., Gros, A., Chagneau, C., Leblanc-Veyrac, P., Samson-Desvignes, N., Baumgärtel, K., Mansuy, I. M., Davis, S., et al. (2013) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2013.0159 · Cited by 81 · see citing works

Common receptors for hallucinogens in rat brain: a comparative autoradiographic study using [125I]LSD and [125I]DOI, a new psychotomimetic radioligand

McKenna, D. J., Nazarali, A. J., Hoffman, A. J., Nichols, D. E., Mathis, C. A., & Saavedra, J. M. (1989) · Brain Research · doi:10.1016/0006-8993(89)91535-7 · Cited by 70 · see citing works

Lysergic acid diethylamide-induced Fos expression in rat brain: role of serotonin-2A receptors

Gresch, P. J., Strickland, L. V., & Sanders‐Bush, E. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00349-4 · Cited by 68 · see citing works

Shaping the renaissance of psychedelic research

Sessa, B. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60600-x · Cited by 66 · see citing works

An animal model of schizophrenia based on chronic LSD administration: Old idea, new results

Marona‐Lewicka, D., Nichols, C. D., & Nichols, D. E. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.006 · Cited by 65 · see citing works

Molecular genetic responses to lysergic acid diethylamide include transcriptional activation of <i>MAP kinase phosphatase‐1, C/EBP‐β</i> and <i>ILAD‐1</i>, a novel gene with homology to arrestins

Nichols, C. D., & Sanders‐Bush, E. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02515.x · Cited by 62 · see citing works

Studies on the involvement of the dopaminergic system in the 5-HT2 agonist (DOI)-induced premature responding in a five-choice serial reaction time task

Koskinen, T., & Sirviö, J. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(00)00425-1 · Cited by 57 · see citing works

PRODUCTION OF ABNORMAL (PSYCHOTIC?) BEHAVIOR IN MICE WITH LYSERGIC ACID DIETHYLAMIDE, AND ITS PARTIAL PREVENTION WITH CHOLINERGIC DRUGS AND SEROTONIN

Woolley, D. W. (1955) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.41.6.338 · Cited by 52 · see citing works

Effects of Lysergic Acid Diethylamide upon Performance of Trained Rats

Winter, C. A., & Flataker, L. (1956) · Experimental Biology and Medicine · doi:10.3181/00379727-92-22453 · Cited by 50 · see citing works

Chronic treatment with LY341495 decreases 5-HT2A receptor binding and hallucinogenic effects of LSD in mice

Moreno, J. L., Holloway, T. D., Rayannavar, V., Sealfon, S. C., & González‐Maeso, J. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2012.12.053 · Cited by 44 · see citing works

Behavioral Changes Over Time Following Ayahuasca Exposure in Zebrafish

Savoldi, R., Polari, D., Pinheiro‐da‐Silva, J., Silva, P. F., Soares, B. L., Yonamine, M., Freire, F. A. D. M., & Luchiari, A. C. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00139 · Cited by 40 · see citing works

In vivo human pharmacodynamics of the psychodysleptic 4-Br-2,5-dimethoxyphenylisopropylamine labelled with 82Br or 77Br

Sargent, T., Kalbhen, D. A., Shulgin, A. T., Braun, G., Stauffer, H., & Kusubov, N. (1975) · Neuropharmacology · doi:10.1016/0028-3908(75)90001-5 · Cited by 40 · see citing works

In-vivo pharmacology of Trace-Amine Associated Receptor 1

Lam, V. M., Espinoza, S., Gerasimov, A. S., Gainetdinov, R. R., & Salahpour, A. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.06.026 · Cited by 36 · see citing works

Implication of the 5-HT2A and 5-HT2C (but not 5HT1A) receptors located within the periaqueductal gray in the elevated plus-maze test–retest paradigm in mice

Gomes, K. S., & Nunes‐de‐Souza, R. L. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.07.015 · Cited by 33 · see citing works

Exploring Hallucinogen Pharmacology and Psychedelic Medicine with Zebrafish Models

Kyzar, E. J., & Kalueff, A. V. (2016) · Zebrafish · doi:10.1089/zeb.2016.1251 · Cited by 29 · see citing works

Cocaine-induced metabolic activation in cortico-limbic circuitry is increased after exposure to the histone deacetylase inhibitor, sodium butyrate

Febo, M., Akbarian, S., Schroeder, F. A., & Ferris, C. F. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.07.065 · Cited by 18 · see citing works

Psychedelics promote structural and functional neural plasticity

Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207 · see citing works

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology &amp; Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506 · see citing works

Effective connectivity changes in LSD-induced altered states of consciousness in humans

Preller, K. H., Razi, A., Zeidman, P., Stämpfli, P., Friston, K. J., & Vollenweider, F. X. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815129116 · Cited by 292 · see citing works

Reviewing the Potential of Psychedelics for the Treatment of PTSD

Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa018 · Cited by 260 · see citing works

Psychedelics as anti-inflammatory agents

Flanagan, T. W., & Nichols, C. D. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1481827 · Cited by 267 · see citing works

Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine

Gregorio, D. D., Aguilar‐Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1659-20.2020 · Cited by 261 · see citing works

A systematic study of microdosing psychedelics

Polito, V., & Stevenson, R. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211023 · Cited by 235 · see citing works

Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review

van Elk, M., & Yaden, D. B. (2022) · Neuroscience &amp; Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104793 · Cited by 221 · see citing works

Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials

Fuentes, J. J., Fonseca, F., Elices, M., Farré, M., & Torrens, M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00943 · Cited by 177 · see citing works

Chronic, Intermittent Microdoses of the Psychedelic <i>N</i> , <i>N</i> -Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents

Cameron, L. P., Benson, C. J., DeFelice, B. C., Fiehn, O., & Olson, D. E. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00692 · Cited by 168 · see citing works

Psychedelics and Other Psychoplastogens for Treating Mental Illness.

Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M., & Olson, D. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727117 · Cited by 166 · see citing works

Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission

De Gregorio, D., Popic, J., Enns, J. P., Inserra, A., Skalecka, A., Markopoulos, A., Posa, L., Lopez-Canul, M., He, Q., Lafferty, C. K., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020705118 · Cited by 139 · see citing works

Mystical and other alterations in sense of self: an expanded framework for studying nonordinary experiences.

Taves, A. (2020) · Perspectives on Psychological Science · doi:10.1177/1745691619895047 · Cited by 140 · see citing works

Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity

Olson, D. E. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00812 · Cited by 135 · see citing works

Updating the dynamic framework of thought: Creativity and psychedelics

Girn, M., Mills, C., Roseman, L., Carhart-Harris, R. L., & Kalina Christoff, A. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.116726 · Cited by 127 · see citing works

Chronic pain and psychedelics: a review and proposed mechanism of action

Castellanos, J. P., Woolley, C., Bruno, K. A., Zeidan, F. Z., Halberstadt, A. L., & Furnish, T. J. (2020) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2020-101273 · Cited by 119 · see citing works

The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT)

Reckweg, J. T., Uthaug, M. V., Szabó, A., Davis, A. K., Lancelotta, R., Mason, N. L., & Ramaekers, J. G. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15587 · Cited by 111 · see citing works

Psychedelic Microdosing: Prevalence and Subjective Effects

Cameron, L. P., Nazarian, A., & Olson, D. E. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1718250 · Cited by 110 · see citing works

The Enactive Approach to Habits: New Concepts for the Cognitive Science of Bad Habits and Addiction

Ramírez–Vizcaya, S., & Froese, T. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.00301 · Cited by 112 · see citing works

Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine

Dunlap, L. E., Andrews, A. M., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00155 · Cited by 106 · see citing works

Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants

Kadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa087 · Cited by 99 · see citing works

Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions

Dinis‐Oliveira, R. J., Pereira, C. L., & da Silva, D. D. (2018) · Current Molecular Pharmacology · doi:10.2174/1874467211666181010154139 · Cited by 101 · see citing works

Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports

Martial, C., Cassol, H., Charland‐Verville, V., Pallavicini, C., Sanz, C., Zamberlán, F., Vivot, R. M., Erowid, F., Erowid, E., Laureys, S., et al. (2019) · Consciousness and Cognition · doi:10.1016/j.concog.2019.01.011 · Cited by 102 · see citing works

Mescaline: The forgotten psychedelic

Vamvakopoulou, I. A., Narine, K. A. D., Campbell, I., Dyck, J. R. B., & Nutt, D. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109294 · Cited by 105 · see citing works

Registered clinical studies investigating psychedelic drugs for psychiatric disorders

Siegel, A. N., Meshkat, S., Benitah, K., Lipsitz, O., Gill, H., Lui, L. M. W., Teopiz, K. M., McIntyre, R. S., & Rosenblat, J. D. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.05.019 · Cited by 97 · see citing works

A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses

Chi, T., & Gold, J. A. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116715 · Cited by 95 · see citing works

d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders

Gregorio, D. D., Enns, J. P., Núñez, N. A., Posa, L., & Gobbi, G. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.07.008 · Cited by 92 · see citing works

Adolescent and adult time trends in US hallucinogen use, 2002–19: any use, and use of ecstasy, LSD and PCP

Livne, O., Shmulewitz, D., Walsh, C. A., & Hasin, D. S. (2022) · Addiction · doi:10.1111/add.15987 · Cited by 92 · see citing works

Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)

Nichols, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00043 · Cited by 91 · see citing works

Depression, mindfulness, and psilocybin: possible complementary effects of mindfulness meditation and psilocybin in the treatment of depression. a review

Heuschkel, K., & Kuypers, K. P. C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00224 · Cited by 86 · see citing works

Effects of External Stimulation on Psychedelic State Neurodynamics

Mediano, P. A. M., Rosas, F. E., Timmermann, C., Roseman, L., Nutt, D., Feilding, A., Kaelen, M., Kringelbach, M. L., Barrett, A. B., Seth, A. K., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00289 · Cited by 84 · see citing works

Dark Classics in Chemical Neuroscience: Mescaline

Cassels, B. K., & Sáez-Briones, P. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00215 · Cited by 85 · see citing works

From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders

Kozłowska, U., Nichols, C. D., Wiatr, K., & Figiel, M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15509 · Cited by 80 · see citing works

Serotonin 2A Receptor (5-HT 2A R) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants

Duan, W., Cao, D., Wang, S., & Cheng, J. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00375 · Cited by 79 · see citing works

Rapid-acting antidepressants

Witkin, J. M., Martin, A. E., Golani, L. K., Xu, N. Z., & Smith, J. L. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.03.002 · Cited by 75 · see citing works

Positive psychology in the investigation of psychedelics and entactogens: a critical review

Jungaberle, H., Thal, S., Zeuch, A., Rougemont-Bücking, A., von Heyden, M., Aicher, H., & Scheidegger, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.034 · Cited by 70 · see citing works

Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property

Higgins, G. A., Carroll, N. K., Brown, M., MacMillan, C., Silenieks, L. B., Thevarkunnel, S., Izhakova, J., Magomedova, L., DeLannoy, I., & Sellers, E. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.640241 · Cited by 70 · see citing works

Classical Psychedelics as Therapeutics in Psychiatry – Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders

Mertens, L. J., & Preller, K. H. (2021) · Pharmacopsychiatry · doi:10.1055/a-1341-1907 · Cited by 65 · see citing works

Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences

Ballentine, G., Friedman, S. F., & Bzdok, D. (2022) · Science Advances · doi:10.1126/sciadv.abl6989 · Cited by 62 · see citing works

Psychedelic‐inspired approaches for treating neurodegenerative disorders

Saeger, H. N., & Olson, D. E. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15544 · Cited by 65 · see citing works

Common neural signatures of psychedelics: Frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition

Atasoy, S., Vohryzek, J., Deco, G., Carhart-Harris, R. L., & Kringelbach, M. L. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.08.009 · Cited by 57 · see citing works

DARK Classics in Chemical Neuroscience: NBOMes

Poulie, C. B. M., Jensen, A. A., Halberstadt, A. L., & Kristensen, J. L. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00528 · Cited by 62 · see citing works

Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 Receptors in the Head Twitch Response Induced by 5-Hydroxytryptophan and Psilocybin: Translational Implications

Shahar, O., Botvinnik, A., Esh-Zuntz, N., Brownstien, M., Wolf, R., Lotan, A., Wolf, G., Lerer, B., & Lifschytz, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214148 · Cited by 61 · see citing works

Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review

Oña, G., & Bouso, J. C. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.09.035 · Cited by 58 · see citing works

More than meets the eye: The role of sensory dimensions in psychedelic brain dynamics, experience, and therapeutics

Aqil, M., & Roseman, L. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109300 · Cited by 58 · see citing works

Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT2AR through simultaneous use of β-arrestin 2 and miniGαq bioassays

Pottie, E., Dedecker, P., & Stove, C. P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114251 · Cited by 55 · see citing works

Activation of 5-HT2 Receptors Reduces Inflammation in Vascular Tissue and Cholesterol Levels in High-Fat Diet-Fed Apolipoprotein E Knockout Mice

Flanagan, T. W., Sebastian, M. N., Battaglia, D. M., Foster, T. P., Maillet, E. L., & Nichols, C. D. (2019) · Scientific Reports · doi:10.1038/s41598-019-49987-0 · Cited by 42 · see citing works

Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies

Calleja‐Conde, J., Morales-Garcia, J. A., Echeverry‐Alzate, V., Bühler, K., Giné, E., & López‐Moreno, J. A. (2022) · Addiction Biology · doi:10.1111/adb.13229 · Cited by 54 · see citing works

Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study

van Elk, M., Fejer, G., Lempe, P., Prochazkova, L., Kuchař, M., Hájková, K., & Marschall, J. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05857-0 · Cited by 52 · see citing works

Lysergic Acid Diethylamide and Psilocybin for the Management of Patients with Persistent Pain: a Potential Role?

Whelan, A., & Johnson, M. I. (2018) · Pain Management · doi:10.2217/pmt-2017-0068 · Cited by 51 · see citing works

Structure-Activity Relationship Analysis of Psychedelics in a Rat Model of Asthma Reveals the Anti-Inflammatory Pharmacophore.

Flanagan, T. W., Billac, G. B., Landry, A. N., Sebastian, M. N., Cormier, S., & Nichols, C. D. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00063 · Cited by 41 · see citing works

Artificial intelligence-driven phenotyping of zebrafish psychoactive drug responses

Bozhko, D. V., Myrov, V. O., Kolchanova, S. M., Polovian, A. I., Galumov, G. K., Demin, K. A., Zabegalov, K. N., Strekalova, T., de Abreu, M. S., Petersen, E. V., et al. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110405 · Cited by 50 · see citing works

Effects of a psychedelic 5-HT2A receptor agonist on anxiety-related behavior and fear processing in mice

Pędzich, B. D., Rubens, S., Sekssaoui, M., Pierre, A., Schuerbeek, A. V., Marin, P., Bockaert, J., Valjent, E., Bécamel, C., & Bundel, D. D. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01324-2 · Cited by 47 · see citing works

Understanding the neurobiological effects of drug abuse: Lessons from zebrafish models

Müller, T. E., Fontana, B. D., Bertoncello, K. T., Franscescon, F., Mezzomo, N. J., Canzian, J., Stefanello, F. V., Parker, M. O., Gerlai, R. T., & Rosemberg, D. B. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109873 · Cited by 46 · see citing works

Rapid-Acting Antidepressants

Witkin, J. M., Knutson, D. E., Rodriguez, G. J., & Shi, S. X.-Y. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180730104707 · Cited by 44 · see citing works

Mindfulness meditation and psychedelics: potential synergies and commonalities

Holas, P., & Kamińska, J. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00551-8 · Cited by 43 · see citing works

Toward Mapping Neurobehavioral Heterogeneity of Psychedelic Neurobiology in Humans

Moujaes, F., Preller, K. H., Ji, J. L., Murray, J. D., Berkovitch, L., Vollenweider, F. X., & Anticevic, A. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.10.021 · Cited by 40 · see citing works

Understanding Central Nervous System Effects of Deliriant Hallucinogenic Drugs through Experimental Animal Models

Volgin, A. D., Yakovlev, O. A., Demin, K. A., Alekseeva, P. A., Kyzar, E. J., Collins, C. J., Nichols, D. E., & Kalueff, A. V. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00433 · Cited by 38 · see citing works

A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder

Barsuglia, J. P., Polanco, M., Palmer, R., Malcolm, B. J., Kelmendi, B., & Calvey, T. (2018) · Progress in Brain Research · doi:10.1016/bs.pbr.2018.08.002 · Cited by 38 · see citing works

Unpredictable Behavior Under the Influence of “Magic Mushrooms”: A Case Report and Review of the Literature

Honyiglo, E., Franchi, A., Cartiser, N., Bottinelli, C., Advenier, A., Bévalot, F., & Fanton, L. (2019) · Journal of Forensic Sciences · doi:10.1111/1556-4029.13982 · Cited by 35 · see citing works

Psychedelic medicine: The biology underlying the persisting psychedelic effects

Kuypers, K. P. C. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.02.029 · Cited by 35 · see citing works

An Improved, Practical, and Scalable Five-Step Synthesis of Psilocybin

Kargbo, R. B., Sherwood, A. M., Meisenheimer, P. L., & Tarpley, G. (2020) · Synthesis · doi:10.1055/s-0039-1691565 · Cited by 33 · see citing works

Novel Psychoactive Phenethylamines: Impact on Genetic Material

Cocchi, V., Gasperini, S., Hrelia, P., Tirri, M., Marti, M., & Lenzi, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249616 · Cited by 33 · see citing works

Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways

Sinha, J. K., Trisal, A., Ghosh, S., Gupta, S., Singh, D. K. K., Han, S. S., Mahapatra, M., Abomughaid, M. M., Abomughayedh, A. M., Almutary, A. G., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102211 · Cited by 31 · see citing works

Are Psychedelic Medicines the Reset for Chronic Pain? Preliminary Findings and Research Needs

Zia, F., Baumann, M., Belouin, S., Dworkin, R., Ghauri, M. H., Hendricks, P. S., Henningfield, J., Lanier, R., Ross, S., & Berger, A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109528 · Cited by 26 · see citing works

Psychedelic control of neuroimmune interactions governing fear

Chung, E. N., Lee, J., Polonio, C. M., Choi, J., Akl, C. F., Kilian, M., Weiß, W. M., Gunner, G., Ye, M., Heo, T. H., et al. (2025) · Nature · doi:10.1038/s41586-025-08880-9 · Cited by 33 · see citing works

Molecular targets of psychedelic‐induced plasticity

Jaster, A. M., Revenga, M. D. L. F., & González‐Maeso, J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15536 · Cited by 30 · see citing works

New Paradigms of Old Psychedelics in Schizophrenia

Mahmood, D., Alenezi, S. K., Anwar, M. J., Azam, F., Qureshi, K. A., & Jaremko, M. (2022) · Pharmaceuticals · doi:10.3390/ph15050640 · Cited by 29 · see citing works

Psychedelics and Anti-inflammatory Activity in Animal Models

Flanagan, T. W., & Nichols, C. D. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_367 · Cited by 29 · see citing works

A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics

Banushi, B., & Polito, V. (2023) · Biology · doi:10.3390/biology12111380 · Cited by 25 · see citing works

Communalistic use of psychoactive plants as a bridge between traditional healing practices and Western medicine: A new path for the Global Mental Health movement

Oña, G., Berrada, A., & Bouso, J. C. (2021) · Transcultural Psychiatry · doi:10.1177/13634615211038416 · Cited by 29 · see citing works

Narratives of the mystical among users of psychedelics

Pedersen, W., Copes, H., & Gashi, L. (2021) · Acta Sociologica · doi:10.1177/0001699320980050 · Cited by 27 · see citing works

Cellular Uptake of Psychostimulants – Are High- and Low-Affinity Organic Cation Transporters Drug Traffickers?

Jensen, O., Rafehi, M., Gebauer, L., & Brockmöller, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.609811 · Cited by 25 · see citing works

Elucidation of the mescaline biosynthetic pathway in peyote (Lophophora williamsii)

Watkins, J. L., Li, Q., Yeaman, S., & Facchini, P. J. (2023) · The Plant Journal · doi:10.1111/tpj.16447 · Cited by 24 · see citing works

Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview

Oña, G., Reverte, I., Rossi, G. N., SANTOS, R. G. D., Hallak, J. E. C., Colomina, M. T., & Bouso, J. C. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231200882 · Cited by 22 · see citing works

If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics

Dworkin, R. H., Anderson, B. T., Andrews, N., Edwards, R. R., Grob, C. S., Ross, S., Satterthwaite, T. D., & Strain, E. C. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.05.003 · Cited by 22 · see citing works

Bedside to bench: the outlook for psychedelic research

Acero, V. P., Cribas, E. S., Browne, K. D., Rivellini, O. M., Burrell, J. C., O’Donnell, J. C., Das, S., & Cullen, D. K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1240295 · Cited by 22 · see citing works

Serotonin-2 Receptor Agonists Produce Anti-inflammatory Effects through Functionally Selective Mechanisms That Involve the Suppression of Disease-Induced Arginase 1 Expression

Flanagan, T. W., Foster, T. P., Galbato, T. E., Lum, P. Y., Louie, B., Song, G., Halberstadt, A. L., Billac, G. B., & Nichols, C. D. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00297 · Cited by 20 · see citing works

Psychedelics elicit their effects by 5-HT2A receptor-mediated Gi signalling

Xu, Z., Wang, H., Yu, J., Deng, Y., Tian, X., Ni, R., Xia, F., Yang, L., Xu, C., Zhang, L., et al. (2026) · Nature · doi:10.1038/s41586-025-10061-7 · Cited by 20 · see citing works

Reaction of N , N -Dimethyltryptamine with Dichloromethane Under Common Experimental Conditions

Dunlap, L. E., & Olson, D. E. (2018) · ACS Omega · doi:10.1021/acsomega.8b00507 · Cited by 19 · see citing works

The Kappa Opioid Receptor and the Sleep of Reason: Cortico-Subcortical Imbalance Following Salvinorin-A

Oña, G., Sampedro, F., Romero, S., Valle, M., Camacho, V., Migliorelli, C., Mañanas, M. Á., Antonijoan, R. M., Puntes, M., Coimbra, J., et al. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab063 · Cited by 18 · see citing works

Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA: Methodological limitations and convergent results

Linguiti, S., Vogel, J. W., Sydnor, V. J., Pines, A. R., Wellman, N., Basbaum, A. I., Eickhoff, C. R., Eickhoff, S. B., Edwards, R. R., Larsen, B., et al. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105421 · Cited by 17 · see citing works

Neuropsychological Functioning in Users of Serotonergic Psychedelics – A Systematic Review and Meta-Analysis

Basedow, L. A., Riemer, T., Reiche, S., Kreutz, R. H., & Majić, T. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.739966 · Cited by 16 · see citing works

Indigenous-Amazonian Traditional Medicine’s Usage of the Tobacco Plant: A Transdisciplinary Ethnopsychological Mixed-Methods Case Study

Berlowitz, I., Torres, E. G., Maake, C., Wolf, U., & Martin-Söelch, C. (2023) · Plants · doi:10.3390/plants12020346 · Cited by 16 · see citing works

Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS

Castillo, A., Dubois, J., Field, R. M., Fishburn, F. A., Gundran, A., Ho, W. C., Jawhar, S., Kates‐Harbeck, J., Aghajan, Z. M., Miller, N., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38258-8 · Cited by 16 · see citing works

Females in Psychedelic Research: A Perspective for Advancing Research and Practice

Cohen, Z. Z., & Blest‐Hopley, G. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00255 · Cited by 15 · see citing works

Psychedelics and schizophrenia: a double-edged sword

Sapienza, J., Martini, F., Comai, S., Cavallaro, R., Spangaro, M., Gregorio, D. D., & Bosia, M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02743-x · Cited by 15 · see citing works

Therapeutic potential of natural psychoactive drugs for central nervous system disorders: A perspective from polypharmacology.

Oña, G., & Bouso, J. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191212103330 · Cited by 14 · see citing works

The association between naturalistic use of psychedelics and co-occurring substance use disorders

Rabinowitz, J., Lev‐Ran, S., & Gross, R. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1066369 · Cited by 14 · see citing works

Serotonergic psychedelic treatment for obesity and eating disorders: potential expectations and caveats for emerging studies

Borgland, S. L., & Neyens, D. M. (2022) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.220090 · Cited by 14 · see citing works

Ayahuasca and Childhood Trauma: Potential Therapeutic Applications

Perkins, D., & Sarris, J. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-55688-4_6 · Cited by 13 · see citing works

Human behavioral pharmacology of psychedelics

Strickland, J. C., & Johnson, M. W. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2021.10.003 · Cited by 13 · see citing works

Single administration of a psychedelic [(R)-DOI] influences coping strategies to an escapable social stress

Krupp, K. T., Yaeger, J. D. W., Ledesma, L. J., Withanage, M. H. H., Gale, J., Howe, C. B., Allen, T. J., Sathyanesan, M., Newton, S. S., & Summers, C. H. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109949 · Cited by 12 · see citing works

Microdosing psychedelics as cognitive and emotional enhancers.

Rifkin, B. D., Maraver, M. J., & Colzato, L. S. (2020) · Psychology of Consciousness Theory Research and Practice · doi:10.1037/cns0000213 · Cited by 12 · see citing works

The Promise of Psychedelic Science

Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00071 · Cited by 12 · see citing works

A Systematic Study of Microdosing PsychedelicsPreprint

Polito, V., & Stevenson, R. J. (2018) · doi:10.31234/osf.io/cw9qs · Cited by 13 · see citing works

Classic psychedelics: the special role of the visual system

Császár-Nagy, N., Kapócs, G., & Bókkon, I. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0092 · Cited by 11 · see citing works

Psychoactive substances for the treatment of neuropsychiatric disorders

Zhen, Z., Sun, X., Yuan, S., & Zhang, J. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104193 · Cited by 9 · see citing works

Commentary: Establishing zebrafish as a model to study the anxiolytic effects of scopolamine

de Abreu, M. S., Friend, A. J., Amstislavskaya, T. G., & Kalueff, A. V. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00293 · Cited by 9 · see citing works

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

Qureshi, O., Cowley, J., Pegg, A., Cooper, A. J., Gordon, J., Brady, C., Belli, A., Butterworth, S., Upthegrove, R., Andrews, N., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70138 · Cited by 10 · see citing works

Seventh Oxford Conference on Biomedicine in Developing Countries organised by the Oxford International Biomedical Center (OIBC) 1–3 April 2001

Asser, R. K. (2002) · Acta Tropica · doi:10.1016/s0001-706x(01)00203-0

P.2.a.046 Abnormal brain responses during social inclusion in depressive illness and effect of acute anti-depressant medication

Kumar, P., Waiter, G. D., Ahearn, T. S., Milders, M. M., Reid, I., & Steele, J. D. (2009) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(09)70595-4

Psychedelics for mental health: a biochemical perspective

González‐Maeso, J. (2024) · The Biochemist · doi:10.1042/bio_2023_161

Psychedelics in Psychiatry

Shinozuka, K., Dumanis, S. B., & Williams, N. (2026) · Springer eBooks · doi:10.1007/978-3-032-31497-0_6

Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience

Omidian, H., & Omidian, A. (2025) · Pharmaceuticals · doi:10.3390/ph18040499 · Cited by 5 · see citing works